LD-2 disclosure · 2nd Quarter - Report
SANOFI U.S. SERVICES, INC.
Client
- Name
- SANOFI U.S. SERVICES, INC.
- Description
- Multinational Pharmaceutical Company.
- Location
- District of Columbia · United States of America
Registrant
- Description
- ​Government affairs and consulting firm.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
4 issuesPharmacy
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. Issues related to Type 1 diabetes screening.
LobbyistsMONICA POPP · HAZEN CLAY MARSHALL
Covered position (MONICA POPP): Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
Covered position (HAZEN CLAY MARSHALL): Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
TargetedSENATE · HOUSE OF REPRESENTATIVES
Copyright/Patent/Trademark
Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act.